Bulk Pharmaceutical API Sources for choline fenofibrate

Bulk Pharmaceutical API Sources for choline fenofibrate

Vendor	Vendor Homepage	Vendor Sku	API Url
MolPort		MolPort-006-393-282
MedChemexpress MCE		HY-14739
AbaChemScene		CS-0893
Chembase.cn		164737
ChemTik		CTK8E8257
Ark Pharm, Inc.		AK119697

Bulk Choline Fenofibrate API: Global Sourcing Landscape

Last updated: February 19, 2026

This analysis details the global supply chain for bulk choline fenofibrate active pharmaceutical ingredient (API), focusing on key manufacturing regions, competitive landscape, regulatory considerations, and market dynamics. The objective is to provide actionable intelligence for procurement professionals and R&D strategists evaluating sourcing options.

Who Are the Primary Manufacturers of Choline Fenofibrate API?

Manufacturing of choline fenofibrate API is concentrated in several key global regions, with significant production capacity in India and China. These regions benefit from established chemical manufacturing infrastructure, lower operational costs, and a large pool of skilled labor. European manufacturers also play a role, often focusing on higher-purity grades and specialized production.

Key Manufacturing Hubs

• India: Dominant producer with numerous large-scale API manufacturers. Companies here offer competitive pricing and high volume capabilities.
  • Example Companies: Divi's Laboratories, Laurus Labs, Aarti Industries. (Note: Specific choline fenofibrate production by these companies is subject to confirmation through direct inquiry and market intelligence.)
• China: A significant manufacturing base with a growing number of API producers. Chinese manufacturers are known for their cost-effectiveness and increasing adherence to international quality standards.
  • Example Companies: Zhejiang Huahai Pharmaceutical, Zhejiang NHU Company, CSPC Pharmaceutical Group. (Note: Specific choline fenofibrate production by these companies is subject to confirmation through direct inquiry and market intelligence.)
• Europe: While smaller in volume compared to Asia, European manufacturers often focus on niche markets, high-quality API, and regulatory compliance for Western markets.
  • Example Companies: Siegfried AG, Lonza Group. (Note: Specific choline fenofibrate production by these companies is subject to confirmation through direct inquiry and market intelligence.)

Comparative Production Capacity

Region	Estimated API Production Capacity (Tonnes/Year)	Key Strengths
India	500 - 1,000	Cost-effectiveness, high volume, established infrastructure
China	400 - 800	Cost-effectiveness, growing quality standards, large chemical industry
Europe	50 - 150	High purity, strict regulatory adherence, specialized production

Estimates are based on general API manufacturing capacity trends for similar lipophilic drug classes and require direct validation for choline fenofibrate.

What are the Dominant Manufacturing Processes for Choline Fenofibrate?

The synthesis of choline fenofibrate typically involves the esterification of fenofibric acid with choline. This process requires careful control of reaction conditions, purification steps, and salt formation to achieve the desired API specifications.

Common Synthetic Routes

1. Fenofibric Acid Synthesis: The precursor, fenofibric acid (2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid), is synthesized through multi-step organic chemistry processes. Common starting materials include 4-chlorobenzoyl chloride and 4-hydroxyphenylacetic acid derivatives.
2. Choline Salt Formation: Fenofibric acid is then reacted with a choline source, such as choline hydroxide or choline bicarbonate, in a suitable solvent. The reaction forms the ester linkage and the choline salt.
3. Purification and Isolation: The crude choline fenofibrate is purified using techniques like crystallization, chromatography, or solvent extraction to remove impurities. The final API is then dried and milled to the required particle size distribution.

Key Process Considerations

• Chiral Purity: While fenofibrate is not chiral, ensuring the absence of chiral impurities from precursor synthesis is crucial.
• Impurity Profiling: Strict control of process-related impurities, residual solvents, and heavy metals is paramount for pharmaceutical grade API. Regulatory agencies require detailed impurity profiles.
• Polymorphism: Like many organic molecules, choline fenofibrate may exhibit polymorphism. Manufacturers must control the crystalline form to ensure consistent bioavailability and stability.
• Particle Size: Particle size distribution significantly impacts dissolution rates and downstream formulation. Manufacturers must demonstrate control over this parameter.

What is the Regulatory Landscape for Choline Fenofibrate API?

Choline fenofibrate API is subject to rigorous regulatory oversight by major health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Compliance with Good Manufacturing Practices (GMP) is mandatory.

Key Regulatory Requirements

• Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, quality control, and stability data.
• GMP Compliance: Facilities must adhere to current GMP standards. Regular inspections by regulatory bodies ensure ongoing compliance. This includes validation of manufacturing processes, analytical methods, and equipment.
• ICH Guidelines: Manufacturers must comply with International Council for Harmonisation (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), ICH Q3A (Impurities in New Drug Substances), and ICH Q11 (Development and Manufacture of Drug Substances).
• Impurity Control: Limits for specific impurities, including genotoxic impurities, are strictly enforced. Manufacturers must demonstrate robust analytical methods for their detection and quantification.
• Stability Studies: Comprehensive stability data, demonstrating the API's shelf-life under various storage conditions, is required.

Recent Regulatory Developments

While no specific recent policy changes directly targeting choline fenofibrate have been widely publicized, the general trend in API regulation emphasizes:

• Increased Scrutiny of Supply Chains: Regulators are increasingly focused on the entire API supply chain, including the origin of raw materials and intermediate steps.
• Data Integrity: Enhanced focus on data integrity across all aspects of pharmaceutical manufacturing and testing.
• Continuous Manufacturing: Exploration and adoption of continuous manufacturing technologies for API production, promising improved consistency and efficiency.

Who Are the Major Purchasers and End-Users of Choline Fenofibrate API?

The primary purchasers of bulk choline fenofibrate API are pharmaceutical companies that formulate and market finished dosage forms (FDFs) of the drug. These companies range from large multinational corporations to smaller generic manufacturers.

Key Purchaser Segments

• Brand-Name Pharmaceutical Companies: Companies holding the original marketing authorization for choline fenofibrate-containing products.
• Generic Pharmaceutical Companies: Manufacturers producing bioequivalent versions of approved choline fenofibrate drugs after patent expiry.
• Contract Development and Manufacturing Organizations (CDMOs): Companies that may procure API on behalf of their pharmaceutical clients for formulation and manufacturing.
• Research and Development Organizations: Academic institutions and biotech companies conducting preclinical or early-stage clinical research with choline fenofibrate.

End-Use Applications

Choline fenofibrate is primarily used for the treatment of hyperlipidemia and hypertriglyceridemia. It is indicated to:

• Reduce elevated triglyceride levels.
• Increase low-density lipoprotein (LDL) cholesterol levels.
• Reduce very low-density lipoprotein (VLDL) cholesterol levels.
• Increase high-density lipoprotein (HDL) cholesterol levels.

The drug's efficacy in managing dyslipidemias makes it a significant therapeutic agent in cardiovascular disease prevention.

What are the Market Dynamics and Pricing Trends for Choline Fenofibrate API?

The market for choline fenofibrate API is influenced by factors such as generic competition, patent expiries, demand from emerging markets, and the overall prevalence of cardiovascular diseases. Pricing is highly competitive, particularly from Asian manufacturers.

Pricing Influences

• Manufacturing Costs: Raw material prices, labor costs, energy expenses, and compliance costs directly impact API pricing.
• Competition: The number of API suppliers and the intensity of competition among them are major drivers of price. A fragmented supplier base typically leads to lower prices.
• Volume Commitments: Large-volume purchase agreements generally secure more favorable pricing.
• Regulatory Status: APIs with approved DMFs and a strong regulatory track record can command higher prices.
• Geopolitical Factors: Trade policies, tariffs, and supply chain disruptions can affect landed costs and market prices.

Typical Price Range

The bulk pricing for choline fenofibrate API can vary significantly based on supplier, quality, volume, and geographical origin. A general indicative range, subject to market fluctuations, could be:

• US\$50 - US\$250 per kilogram

This range is an estimation and requires direct engagement with manufacturers and market intelligence platforms for precise, real-time pricing.

Market Trends

• Growth in Generic Market: As patents expire, the demand for choline fenofibrate API from generic manufacturers is expected to grow, increasing competition among API suppliers.
• Emerging Market Demand: Increasing awareness and diagnosis of hyperlipidemia in emerging economies are expected to drive demand for affordable generic treatments.
• Supply Chain Diversification: Pharmaceutical companies are increasingly looking to diversify their API sourcing to mitigate risks, potentially benefiting manufacturers in regions beyond the traditional dominant players.
• Focus on Quality and Compliance: While cost remains a factor, there is a growing emphasis on API quality, regulatory compliance, and supply chain transparency.

What are the Potential Risks and Challenges in Sourcing Choline Fenofibrate API?

Sourcing choline fenofibrate API involves navigating several potential risks and challenges, from supply chain vulnerabilities to quality control issues.

Key Risks and Challenges

• Supply Chain Disruption: Geopolitical instability, natural disasters, or pandemics can disrupt manufacturing and logistics, leading to shortages and price volatility. Reliance on a single supplier or region exacerbates this risk.
• Quality Control Failures: Inconsistent quality, contamination, or deviations from GMP can lead to regulatory actions, product recalls, and reputational damage. Thorough due diligence and robust quality agreements are essential.
• Intellectual Property (IP) Issues: While primary patents for fenofibrate have long expired, process patents related to novel manufacturing routes or crystalline forms could still exist, requiring careful IP assessment.
• Regulatory Hurdles: Changes in regulatory requirements, delays in DMF review, or inspection failures can impede market access and product launch timelines.
• Currency Fluctuations: For international sourcing, currency exchange rate volatility can impact the actual cost of API procurement.
• Environmental Regulations: Increasing environmental regulations in manufacturing regions can lead to higher production costs or temporary shutdowns if compliance is not maintained.

Mitigation Strategies

• Supplier Audits: Conduct thorough on-site audits of potential API manufacturers to assess their facilities, quality systems, and regulatory compliance.
• Quality Agreements: Establish comprehensive quality agreements with suppliers that clearly define specifications, testing protocols, change control procedures, and responsibilities.
• Dual Sourcing: Qualify at least two independent suppliers to ensure continuity of supply and provide leverage in negotiations.
• Contingency Planning: Develop robust contingency plans to address potential supply chain disruptions, including identifying alternative logistics providers and safety stock levels.
• Regulatory Intelligence: Maintain up-to-date knowledge of evolving regulatory requirements in target markets.
• Contractual Safeguards: Include clear terms regarding quality, delivery, pricing, and intellectual property protection in supplier contracts.

Key Takeaways

• Dominant Production: India and China are the primary global sources for bulk choline fenofibrate API, offering high volume and cost-effectiveness.
• Regulatory Scrutiny: API manufacturing must adhere to stringent GMP standards and comply with regulations from agencies like the FDA and EMA, necessitating comprehensive DMF submissions.
• Competitive Landscape: The market is highly competitive, with pricing influenced by production costs, volume commitments, and the number of qualified suppliers.
• Supply Chain Risks: Sourcing involves risks related to supply chain disruptions, quality control failures, and evolving regulatory requirements. Diversification of suppliers and robust quality agreements are critical.
• Market Demand: Demand is driven by the therapeutic need for lipid management, with growth expected from the generic market and emerging economies.

Frequently Asked Questions

1. What are the typical lead times for sourcing bulk choline fenofibrate API from India or China? Lead times for bulk choline fenofibrate API typically range from 6 to 12 weeks from order placement to delivery, depending on current manufacturing schedules, order volume, and shipping logistics.

2. Are there specific impurity limits that pharmaceutical companies must adhere to for choline fenofibrate API? Yes, pharmaceutical companies must adhere to impurity limits as specified in pharmacopoeial monographs (e.g., USP, EP) and as detailed in their approved marketing authorizations, often guided by ICH Q3A guidelines. Specific limits for known and unknown impurities, residual solvents, and heavy metals are critical.

3. What is the shelf life typically guaranteed for choline fenofibrate API by manufacturers? Choline fenofibrate API manufacturers typically guarantee a shelf life of 2 to 3 years when stored under specified conditions (e.g., protected from light and moisture). This is supported by comprehensive stability study data.

4. How can a company verify the GMP compliance of an overseas API manufacturer? Verification of GMP compliance can be achieved through independent third-party audits, review of the manufacturer's latest regulatory inspection reports (e.g., FDA or EMA inspection history), examination of their quality management system documentation, and review of their Drug Master File (DMF).

5. What are the implications of fenofibrate's patent expiry on the choline fenofibrate API market? The patent expiry of the innovator fenofibrate products has led to increased generic competition, which in turn drives demand for cost-effective choline fenofibrate API. This has intensified price competition among API manufacturers and encouraged the entry of new suppliers, particularly from Asia.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Specific URL for DMF information if available, otherwise general link to FDA site] [2] European Medicines Agency. (n.d.). Active substances. Retrieved from [EMA Website - Specific URL for Active Substances information if available, otherwise general link to EMA site] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline Q11: Development and Manufacture of Drug Substances. [5] United States Pharmacopeia. (n.d.). USP-NF Online. Retrieved from [USP Website - Specific URL for pharmacopoeial information if available, otherwise general link to USP site]